☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
pfizer
Pfizer Reports the EC’s Conditional Approval of Durveqtix (Fidanacogene Elaparvovec) for the Treatment of Hemophilia B
July 26, 2024
Pfizer Reports Topline Data from P-III Trial of Giroctocogene Fitelparvovec for Treating Hemophilia A
July 24, 2024
Pfizer Reports the Advancement of Danuglipron Development
July 11, 2024
Pfizer and BioNTech Report the CHMP’s Positive Opinion of Comirnaty JN.1 Vaccine for COVID-19
June 28, 2024
Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy
June 13, 2024
Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)
June 3, 2024
Load more...
Back to Home